Noven Pharmaceuticals, Inc. | Private | JDS Pharmaceuticals | Private | Advisory: For Buyer | 125 | | |
Focal, Inc | Private | Genzyme BioSurgery | now NYSE:SNY | Advisory: For Seller | 15 | | |
RGene Therapeutics, Inc. | Private | Targeted Genetics | NASDAQ: TGEN | Advisory: For Seller | 25 | | |
BioCryst Pharmaceuticals Inc | NasdaqGS: BCRX | Johnson & Johnson | NYSE: JNJ | Advisory: JT Venture | 60 | | |
Hemispherx Biopharma, Inc. | AMEX: HEB | Biken Corporation | Private | Advisory: JT Venture | N/A | | |
SK Biopharmaceuticals | Private | Johnson & Johnson | NYSE: JNJ | Advisory: License | 80 | | |
Nitromed , Inc | Private | Johnson & Johnson | NYSE: JNJ | Advisory: License | 60 | | |
MicroDose Therapeutx, Inc. | Private | Novartis and Bristol- Meyers Squibb | NYSE: NVS NYSE: BMY | Advisory: License | 20 | | |
NatImmune | Private | Enzon | OTCMKTS: ENZN | Advisory: License | 125 | | |
NitroMed Inc. | Private | British Oxygen Corporation | Private | Advisory: License | N/A | | |
Apoptosis | Private | N/A | NYSE: JNJ | As Board Member | N/A | | |
Augmenta Biologicals, LLC | Private | N/A | N/A | As Board Member | N/A | | |
TurnPoint Medical Devices, inc. | Private | N/A | N/A | As Board Member | N/A | | |
i-STAT | Private | Abbott Laboratories | NYSE: ABT | As Founder | 392 | | |
Melanovus Oncology | Private | N/A | N/A | As CEO | N/A | | |
Southern Lights Ventures 2002 Limited | Private | N/A | NYSE: ABT | As Founder and Senior Executive | N/A | | |
Integra Life Sciences Corporation | (NasdaqGS: IART) | N/A | N/A | As Founder and Senior Executive | N/A | | |
Engelhard Corp | Part of BASF | N/A | N/A | As Senior Executive | N/A | | |
Engelhard Industries Inc. | Private | Dupont (environmental business) | NYSE: DDPB | As Senior Executive | 15 | | |
Enzon Pharmaceuticals, Inc. | OTCPK: ENZN | Genex Corporation | OTCMKTS: GENX | As Senior Executive | N/A | | |
Enzon Pharmaceuticals, Inc. | OTCPK: ENZN | Schering-Plough | now NYSE: MRK | As Senior Executive | N/A | | |
Enzon Pharmaceuticals, Inc. | OTCPK: ENZN | Rhone Poulenc Rorer | Private | As Senior Executive | N/A | | |
Halcon International, Inc. | Private | Atlantic Richfield Company, Inc. | Private | As Senior Executive | 1000 | | |
ImmuneTech, Inc. | Private | Dura Pharmaceuticals, Inc. | Private | As Senior Executive | N/A | | |
Oncotherapeutics, Inc. | Private | N/A | N/A | As Senior Executive | N/A | | |
VectraMed Inc. | Private | Aventis | now NYSE:SNY | As Senior Executive | N/A | | |
VectraMed Inc. | Private | Elan Corporation Limited | Private | As Senior Executive | N/A | | |
VectraMed Inc. | Private | Ethicon, Inc. | NYSE: JNJ | As Senior Executive | N/A | | |
VectraMed Inc. | Private | Pfizer, Inc. | NYSE: PFE | As Senior Executive | N/A | | |
Virium Pharmaceuticals, Inc. | Private | Macrochem | OTCBB: MACM | As Senior Executive | N/A | | |
Pacific Biotech Research Associates | Private | New England Nuclear (DuPont) | NYSE:DD | Licensing Rights as Principal / President | N/A | | |
Xeotron Corp | Private | VC Investors | Private | Seed Round as Principal / CEO | 10 | | |
Xeotron Corp | Private | Universities of Houston and Michigan | Private | Licenses as Principal / CEO | N/A | | |
Targeted Genetics | Private | Investors | Private | Secondary offering, NASDAQ as Principal | 30 | | |
RGene Therapeutics | Private | Groupe Fournier (Solvay, Abbott) | OTC: SOLVY NYSE: ABT | Codevelopment, License & Marketing as Principal / CEO | 12 | | |
RGene Therapeutics | Private | Pasteur-Meriuex (Sanofi) | NASDAQ: SNY | License as Principal | N/A | | |
Schering-Plough (Merck) | NYSE:MRK | Sandoz (Novartis) | NYSE: NVS | Co-develop renegoatiation as Principal / President | N/A | | |
Fannin Innovation Studio | Private | Investors Institutions | Private | Technology / Startup Acquisitions as Principal / President | N/A | | |
Fannin Innovation Studio | Private | NIH, Federal and State Agencies | Private | Development Grants as Principal / President | N/A | | |
Fannin Innovation Studio | Private | Investors | Private | Recapitalization as Principal / President | N/A | | |
Aclipse Therapeutics | Private | N/A | N/A | CFO | N/A | | |
AIM Immunotech | NYSE/AMEX: AIM | N/A | N/A | CFO | N/A | | |
Enveric Biosciences | NasdaqCM: ENVB | N/A | N/A | CFO | N/A | | |
NLS Pharmaceutics | NasdaqCM:NLSP | N/A | N/A | CFO through successful IPO | N/A | | |
SFA Therapeutics, Inc. | Private | N/A | N/A | CFO and Board Member | N/A | | |
Sharp Edge Labs | Private | N/A | N/A | CFO / COO | N/A | | |
Vitruviae Therapeutics | Private | N/A | N/A | Senior Financial Advisor | N/A | | |
Motif Bio | Nasdaq: MTFB | N/A | N/A | CFO | N/A | | |
StemCyte | Private | N/A | N/A | Senior VP, CFO and Business Unit Manager | N/A | | |
Tyme Technologies, Inc. | Nasdaq: TYME | N/A | N/A | Senior Financial Advisor | N/A | | |
ProCyte | Private | N/A | N/A | Advisory: Prefunding Intelligence | N/A | | |